| Business Summary | | SciClone
Pharmaceuticals,
Inc.
develops
and
commercializes
novel
medicines
for
treating
a
broad
range
of
diseases.
The
Company
has
focused
its
product
development
and
commercial
activities
on
hepatitis
C,
hepatocellular
carcinoma,
malignant
melanoma,
hepatitis
B,
HIV,
drug-resistant
tuberculosis
and
cystic
fibrosis.
The
Company's
flagship
drug
is
Zadaxin,
which
boosts
the
body's
immune
system
in
the
fight
against
multiple
types
of
cancer
and
infectious
diseases.
The
Company's
second
product
in
clinical
development,
CPX,
is
a
novel
protein-repair
therapy
for
cystic
fibrosis.
Additional
drug
candidates
in
its
pipeline
include
SCV-07,
the
lead,
orally
active,
compound
in
its
new
class
of
immune
system
enhancer
drugs,
and
DAX.
SCV-07
has
entered
phase
I
testing
for
drug-resistant
tuberculosis
and
the
Company
expect
to
develop
SCV-07
for
cancer
and
viral
hepatitis.
DAX
is
targeted
at
cystic
fibrosis. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SciClone
is
a
global
biopharmaceutical
company
that
acquires,
develops
and
commercializes
specialist-oriented
drugs
for
treating
chronic
and
life-threatening
diseases.
For
the
six
months
ended
6/30/01,
revenues
decreased
17%
to
$6.4
million.
Net
loss
totalled
$4.3
million,
up
from
$1.5
million.
Revenues
reflect
lower
sales
to
importing
agents
in
the
People's
Republic
of
China.
Higher
loss
suffered
from
an
increase
in
marketing
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Jere Goyan, Ph.D., 70 Chairman | -- | Donald Sellers, 56 Pres,
CEO | $863K | Richard Waldron, 47 CFO | -- | Alfred Rudolph, M.D., 53 COO | 316K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|